Rameen Beroukhim

List of Publications by Citations

133 papers	25,865 citations	64 h-index	147 g-index
147 ext. papers	33,397 ext. citations	16.9 avg, IF	6.11 L-index

#	Paper	IF	Citations
133	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
132	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
131	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
130	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biology*, **2011**, 12, R41	18.3	1614
129	Absolute quantification of somatic DNA alterations in human cancer. *Nature Biotechnology*, **2012**, 30, 413-21	44.5	1229
128	Pan-cancer patterns of somatic copy number alteration. *Nature Genetics*, **2013**, 45, 1134-40	36.3	1198
127	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, **2016**, 164, 550-63	56.2	1140
126	Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18	56.2	854
125	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20007-12	11.5	812
124	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature Medicine*, **2018**, 24, 679-690	50.5	659
123	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discovery*, **2015**, 5, 1164-1177	24.4	581
122	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nature Genetics*, **2013**, 45, 478-86	36.3	558
121	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
120	Highly parallel identification of essential genes in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20380-5	11.5	424
119	Patient-derived xenografts undergo mouse-specific tumor evolution. *Nature Genetics*, **2017**, 49, 1567-1575	36.3	384
118	Genetic and transcriptional evolution alters cancer cell line drug response. *Nature*, **2018**, 560, 325-330	50.4	379
117	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3	24.3	377

116	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Research*, **2009**, 69, 4674-81	10.1	327
115	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7	10.6	320
114	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. *Science*, **2018**, 360, 331-335	33.3	255
113	Patterns of somatic structural variation in human cancer genomes. *Nature*, **2020**, 578, 112-121	50.4	232
112	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*, **2018**, 33, 721-735.e8	24.3	228
111	BET bromodomain inhibition of MYC-amplified medulloblastoma. *Clinical Cancer Research*, **2014**, 20, 912-25	12.9	227
110	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. *Nature Medicine*, **2014**, 20, 732-40	50.5	213
109	Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. *Nature Communications*, **2015**, 6, 6169	17.4	185
108	Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature*, **2020**, 580, 517-523	50.4	172
107	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. *Science*, **2019**, 363, 1217-1222	33.3	165
106	Cancer vulnerabilities unveiled by genomic loss. *Cell*, **2012**, 150, 842-54	56.2	163
105	Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. *Pediatric Blood and Cancer*, **2014**, 61, 1173-9	3	158
104	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. *Cell*, **2018**, 174, 433-447.e19	56.2	155
103	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nature Genetics*, **2016**, 48, 273-82	36.3	154
102	Longitudinal molecular trajectories of diffuse glioma in adults. *Nature*, **2019**, 576, 112-120	50.4	151
101	SvABA: genome-wide detection of structural variants and indels by local assembly. *Genome Research*, **2018**, 28, 581-591	9.7	149
100	Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. *Cancer Cell*, **2012**, 21, 547-62	24.3	145
99	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. *Neuro-Oncology*, **2016**, 18, 649-55	1	144

98	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. *Nature Genetics*, **2016**, 48, 848-55	36.3	135
97	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nature Medicine*, **2018**, 24, 968-977	50.5	126
96	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. *Nature Genetics*, **2014**, 46, 588-94	36.3	124
95	Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. *PLoS Computational Biology*, **2006**, 2, e41	5	124
94	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 232-7	11.5	112
93	SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. *Cancer Cell*, **2013**, 24, 738-50	24.3	111
92	Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. *Genome Research*, **2013**, 23, 228-35	9.7	109
91	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. *Cancer Cell*, **2020**, 37, 104-122.e12	24.3	107
90	SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. *Molecular Cell*, **2014**, 56, 595-607	17.6	105
89	Extent of resection and overall survival for patients with atypical and malignant meningioma. *Cancer*, **2015**, 121, 4376-81	6.4	105
88	Genomic evolution of cancer models: perils and opportunities. *Nature Reviews Cancer*, **2019**, 19, 97-109	31.3	104
87	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. *Neuro-Oncology*, **2015**, 17, 862-7	1	84
86	Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. *Nature Genetics*, **2020**, 52, 294-305	36.3	81
85	Genomic landscape of high-grade meningiomas. *Npj Genomic Medicine*, **2017**, 2,	6.2	78
84	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). *Neuro-Oncology*, **2019**, 21, ii70-ii71	1	78
83	LGG-04. CLINICO-HISTO-MOLECULAR LANDSCAPE OF EIGHTY-TWO PEDIATRIC AND YOUNG ADULT DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS. *Neuro-Oncology*, **2019**, 21, ii99-ii99	1	78
82	MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION. *Neuro-Oncology*, **2019**, 21, ii110-ii111	1	78
81	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. *Neuro-Oncology*, **2014**, 16, v16-v16	1	78

80	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. *Neuro-Oncology*, **2020**, 22, iii443-iii443	1	78
79	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. *Neuro-Oncology*, **2020**, 22, iii373-iii373	1	78
78	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). *Neuro-Oncology*, **2020**, 22, iii297-iii297	1	78
77	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. *Neuro-Oncology*, **2018**, 20, vi271-vi271	1	78
76	INNV-22. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. *Neuro-Oncology*, **2018**, 20, vi142-vi143	1	78
75	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. *Neuro-Oncology*, **2018**, 20, vi161-vi161	1	78
74	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. *Neuro-Oncology*, **2018**, 20, vi76-vi76	1	78
73	The genomic landscape of schwannoma. *Nature Genetics*, **2016**, 48, 1339-1348	36.3	74
72	Cas9 activates the p53 pathway and selects for p53-inactivating mutations. *Nature Genetics*, **2020**, 52, 662-668	36.3	69
71	Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. *Genes and Development*, **2014**, 28, 1957-75	12.6	66
70	Radiographic prediction of meningioma grade by semantic and radiomic features. *PLoS ONE*, **2017**, 12, e0187908	3.7	66
69	Landscape of Genomic Alterations in Pituitary Adenomas. *Clinical Cancer Research*, **2017**, 23, 1841-1851	12.9	64
68	Genomic landscape of intracranial meningiomas. *Journal of Neurosurgery*, **2016**, 125, 525-35	3.2	62
67	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. *Neurology*, **2015**, 84, 280-6	6.5	62
66	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. *Neuro-Oncology*, **2014**, 16, 1547-53	1	61
65	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology*, **2017**, 19, 535-545	1	60
64	ARID1A and TERT promoter mutations in dedifferentiated meningioma. *Cancer Genetics*, **2015**, 208, 345-50	2.9	57
63	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. *Nature Structural and Molecular Biology*, **2015**, 22, 703-711	17.6	56

62	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. *Cancer Cell*, **2020**, 37, 639-654.e6	24.3	56
61	MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. *Stem Cell Reports*, **2017**, 8, 1497-1505	8	49
60	Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. *ELife*, **2017**, 6,	8.9	49
59	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. *Oncotarget*, **2014**, 5, 10596-606	3.3	46
58	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. *Oncotarget*, **2014**, 5, 8083-92	3.3	46
57	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. *Cell*, **2020**, 183, 197-210.e32	56.2	45
56	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. *Endocrinology*, **2017**, 158, 2284-2291	4.8	42
55	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. *Neuro-Oncology*, **2017**, 19, 986-996	1	39
54	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. *Neuro-Oncology*, **2015**, 17, 1344-55	1	39
53	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. *Journal of Neuro-Oncology*, **2016**, 128, 293-302	4.8	36
52	miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. *Oncogene*, **2019**, 38, 2923-2936	9.2	36
51	MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. *Cancer Discovery*, **2016**, 6, 45-58	24.4	35
50	Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. *Nature*, **2021**, 590, 486-491	50.4	34
49	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. *Neuro-Oncology*, **2015**, 17, 1486-96	1	33
48	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. *Cancer Cell*, **2018**, 34, 922-938.e7	24.3	31
47	Genomic profile of human meningioma cell lines. *PLoS ONE*, **2017**, 12, e0178322	3.7	30
46	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22	56.2	29
45	Myxopapillary ependymomas in children: imaging, treatment and outcomes. *Journal of Neuro-Oncology*, **2016**, 126, 165-174	4.8	28

44	Pediatric low-grade gliomas: how modern biology reshapes the clinical field. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1845, 294-307	11.2	28
43	Tyrosine receptor kinase B is a drug target in astrocytomas. *Neuro-Oncology*, **2017**, 19, 22-30	1	26
42	Copy number alterations unmasked as enhancer hijackers. *Nature Genetics*, **2016**, 49, 5-6	36.3	25
41	Genomic and Epigenomic Landscape in Meningioma. *Neurosurgery Clinics of North America*, **2016**, 27, 167-79	4	24
40	MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. *Oncotarget*, **2016**, 7, 37054-37063	3.3	24
39	Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. *Neoplasia*, **2017**, 19, 75-83	6.4	23
38	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. *PLoS ONE*, **2017**, 12, e0176045	3.7	22
37	Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. *Nature Communications*, **2020**, 11, 2517	17.4	21
36	Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. *ELife*, **2019**, 8,	8.9	20
35	Selective and mechanistic sources of recurrent rearrangements across the cancer genome		20
34	Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. *Neuro-Oncology*, **2014**, 16, 1523-9	1	19
33	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nature Communications*, **2019**, 10, 2400	17.4	18
32	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. *Molecular Cell*, **2020**, 78, 1207-1223.e8	17.6	18
31	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. *Nature Communications*, **2019**, 10, 3731	17.4	17
30	Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. *Nature Genetics*, **2020**, 52, 219-230	36.3	15
29	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. *Neuro-Oncology*, **2017**, 19, 908-917	1	14
28	VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules. *Bioinformatics*, **2016**, 32, 2029-31	7.2	14
27	Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. *Epilepsy Research*, **2014**, 108, 843-52	3	13

26	Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. *Scientific Reports*, **2016**, 6, 25521	4.9	11
25	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. *American Journal of Neuroradiology*, **2020**, 41, 874-881	4.4	10
24	Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 334-345	12.9	9
23	Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids. *ACS Chemical Biology*, **2020**, 15, 1358-1369	4.9	8
22	Novel patterns of complex structural variation revealed across thousands of cancer genome graphs		8
21	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. *Diagnostic Pathology*, **2016**, 11, 13	3	8
20	Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. *Neuro-Oncology*, **2021**,	1	7
19	Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. *Cell Reports*, **2021**, 34, 108707	10.6	7
18	A Molecularly Integrated Grade for Meningioma. *Neuro-Oncology*, **2021**,	1	7
17	SvABA: Genome-wide detection of structural variants and indels by local assembly		5
16	SeqLib: a C ++ API for rapid BAM manipulation, sequence alignment and sequence assembly. *Bioinformatics*, **2017**, 33, 751-753	7.2	5
15	Quantification of aneuploidy in targeted sequencing data using ASCETS. *Bioinformatics*, **2021**, 37, 2461-2463	7.6	4
14	The Tangent copy-number inference pipeline for cancer genome analyses		3
13	CloneSifter: enrichment of rare clones from heterogeneous cell populations. *BMC Biology*, **2020**, 18, 177	7.3	3
12	TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. *Molecular Cell*, **2021**, 81, 2583-2595.e6	17.6	3
11	Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. *Neuro-Oncology*, **2021**,	1	3
10	CANCER. The oncogene makes its escape. *Science*, **2016**, 351, 1398-9	33.3	2
9	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi204-vi205	1	2

8	Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. *Genome Medicine*, **2021**, 13, 114	14.4	2
7	HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA. *Neuro-Oncology*, **2020**, 22, iii351-iii351	1	1
6	DNA-based copy number analysis confirms genomic evolution of PDX models.. *Npj Precision Oncology*, **2022**, 6, 30	9.8	1
5	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.. *Nature Communications*, **2022**, 13, 604	17.4	0
4	Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. *STAR Protocols*, **2021**, 2, 100483	1.4	0
3	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. *Neuro-Oncology*, **2022**, 24, i101-i102	1	
2	RARE-22 Characterizing the landscape of structural variants in adamantinomatous craniopharyngioma. *Neuro-Oncology*, **2022**, 24, i14-i14	1	
1	LGG-45. Genetic dependencies inMYB/MYBL1-driven pediatric low-grade glioma models. *Neuro-Oncology*, **2022**, 24, i98-i98	1	